Abstract

PRM152 - The Quality-Adjusted Time Without Symptoms and Toxicity (Q-TWIST) in (IMMUNO)-Oncology: A Systematic Review of the Literature

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
PRM79 - Systematic review of the Q-TWiST in oncology
C.T Solem ... M.F Botteman
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 17
C.T Solem, et. al.C.T Solem ... M.F Botteman
01 May 2014
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
Jeff P Sharman ... Priyanka Gaitonde
Leukemia and Lymphoma | VOL. 64
Jeff P Sharman, et. al.Jeff P Sharman ... Priyanka Gaitonde
23 May 2023
A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients
John F Seymour ... Anthony R Mato
Blood | VOL. 138
John F Seymour, et. al.John F Seymour ... Anthony R Mato
05 Nov 2021
A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.
Ian Chau ... Alejandro Moreno-Koehler
Journal of Clinical Oncology | VOL. 42
Ian Chau, et. al.Ian Chau ... Alejandro Moreno-Koehler
20 Jan 2024
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?
Reza Yaesoubi
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Reza YaesoubiReza Yaesoubi
06 Jul 2024
Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism
Darius N Lakdawalla ... Hong-Hanh Nguyen
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Darius N Lakdawalla, et. al.Darius N Lakdawalla ... Hong-Hanh Nguyen
06 Jul 2024
Generating utilities for the CS-Base: a novel, generic, and patient-centered health-outcome measure
Xin Zhang ... Paul Fm Krabbe
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Xin Zhang, et. al.Xin Zhang ... Paul Fm Krabbe
06 Jul 2024
EQ-5D-5L population scores in mainland China: results from a nationally representative survey 2021
Qiang Yao ... Chaojie Liu
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Qiang Yao, et. al.Qiang Yao ... Chaojie Liu
06 Jul 2024
View more papers